Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06577220 · ClinicalTrials.gov registry record · NA
Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement
A NA study of Cervical Cancer and Human Papillomavirus Infection, sponsored by Baylor College of Medicine.
- Active
- Registry status
- NA
- Development phase
- 111
- Enrollment target
- 1
- Study location
NCT06577220: Active NA study of Cervical Cancer and Human Papillomavirus Infection, sponsored by Baylor College of Medicine.
NCT06577220 is a NA study of Cervical Cancer and Human Papillomavirus Infection that is active but no longer recruiting, run by Baylor College of Medicine. The registered enrollment target is 111 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06577220, a NA study of Cervical Cancer and Human Papillomavirus Infection, is active but no longer recruiting, sponsored by Baylor College of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
Regularly attending for Pap test cervical cancer screening in a clinic is often unfeasible and/or unacceptable to many women and persons with a cervix. This study is a supplement to increase representation of Asian and Asian American women in a pragmatic clinical trial that evaluates if mailing and testing self-sampled kits for high-risk human papillomavirus (HPV) can cost-effectively increase screening participation among underserved minority women in a safety-net health system.
Primary Outcome
completion and return of a mailed self-sample HPV testing kit that is adequate for testing (i.e., does not produce unsatisfactory results) or attendance for clinic-based screening
Conditions Studied
Interventions
- BEHAVIORAL Patient Navigation
- BEHAVIORAL Telephone Recall
- BEHAVIORAL Mailed HPV Self-Sampling Kit
Study Locations (1)
Texas
- Harris Health System - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2026-01-24 |
| Phase | NA |
What the registry record for NCT06577220 still lists
NCT06577220 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 3 interventions - of which Patient Navigation is the first listed.
NCT06577220 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06577220 about?
NCT06577220 is a clinical study titled "Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement". Regularly attending for Pap test cervical cancer screening in a clinic is often unfeasible and/or unacceptable to many women and persons with a cervix. This study is a supplement to increase representation of Asian and Asian American women in a pragmatic clinical trial that evaluates if mailing and ...
What is the current status of trial NCT06577220?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 111 participants. The study started on 2023-09-28. Estimated completion is 2026-01-24.
What conditions does trial NCT06577220 study?
This clinical trial studies the following conditions: Cervical Cancer, Human Papillomavirus Infection.
What interventions are being tested in trial NCT06577220?
The interventions under investigation include: Patient Navigation (BEHAVIORAL), Telephone Recall (BEHAVIORAL), Mailed HPV Self-Sampling Kit (BEHAVIORAL).
Who is sponsoring clinical trial NCT06577220?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06577220 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06577220's enrollment target sits among peer trials
111 66th of 144 higher than 78 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI